August 6, 2025. Labiotech.eu.
Fusion proteins have long been on the market to treat several diseases, including cancer, autoimmune, and rare conditions. These therapeutic agents have caught the attention of biopharma and investors alike these past months attracting dollars from deep pockets in the pursuit of commercial success. Nomlabofusp developer Larimar Therapeutics $69 million public offering.